Evidence map›Paper›PMID 33658570›Full record

ArticleScientific reports2021

Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.

Daphne Li, Erin R Bonner, Kyle Wierzbicki, Eshini Panditharatna, Tina Huang, Rishi Lulla, Sabine Mueller, Carl Koschmann, Javad Nazarian, Amanda M Saratsis

Open access · goldAbstract readValidation Study
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 3 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 2 countries.

Daphne Li *Department of Neurological Surgery, Loyola University Medical Center, Maywood, IL, USA.
Erin R Bonner *Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC, USA.
Kyle WierzbickiDepartment of Pediatric Hematology/Oncology, University of Michigan Medical Center, Ann Arbor, MI, USA.
Eshini PanditharatnaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tina HuangDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Rishi LullaDepartment of Pediatric Hematology/Oncology, Brown Alpert Medical School, Providence, Rhode Island, USA.
Sabine MuellerDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Carl KoschmannDepartment of Pediatric Hematology/Oncology, University of Michigan Medical Center, Ann Arbor, MI, USA.
Javad NazarianCenter for Genetic Medicine Research, Children's National Medical Center, Washington, DC, USA. javad.nazarian@kispi.uzh.ch.
Amanda M SaratsisDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. amanda.saratsis@gmail.com.
Neurological Surgery · USUniversity of Michigan–Ann Arbor · USBrown University · USChildren's National · USDana-Farber Cancer Institute · USLoyola University Medical Center · USUniversity Children's Hospital Zurich · CHUniversity of California, San Francisco · US

Funding

Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
Northwestern University Clinical and Translational Science Institute (NUCATS)KL2TR001424 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SHARMA, LEENA · 2015 to 2023
$8.1M
Investigation of Histone H3 Post-Translational Modifications in Pediatric Brainstem GliomaK08NS097624 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SARATSIS, AMANDA MUHS · 2016 to 2022
$918k
Targeting ATRX-Deficient Pediatric GBMK08NS099427 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOSCHMANN, CARL J · 2017 to 2021
$811k
NCATS NIH HHS KL2 TR001424NCATS NIH HHS UL1 TR001422NINDS NIH HHS K08 NS097624NINDS NIH HHS K08NS097624NINDS NIH HHS K08 NS099427
6 · The paper itself

Abstract

Diffuse midline glioma (DMG) is a highly morbid pediatric brain tumor. Up to 80% of DMGs harbor mutations in histone H3-encoding genes, associated with poor prognosis. We previously showed the feasibility of detecting H3 mutations in circulating tumor DNA (ctDNA) in the liquid biome of children diagnosed with DMG. However, detection of low levels of ctDNA is highly dependent on platform sensitivity and sample type. To address this, we optimized ctDNA detection sensitivity and specificity across two commonly used digital droplet PCR (ddPCR) platforms (RainDance and BioRad), and validated methods for detecting H3F3A c.83A > T (H3.3K27M) mutations in DMG CSF, plasma, and primary tumor specimens across three different institutions. DNA was extracted from H3.3K27M mutant and H3 wildtype (H3WT) specimens, including H3.3K27M tumor tissue (n = 4), CSF (n = 6), plasma (n = 4), and human primary pediatric glioma cells (H3.3K27M, n = 2; H3WT, n = 1). ctDNA detection was enhanced via PCR pre-amplification and use of distinct custom primers and fluorescent LNA probes for c.83 A > T H3F3A mutation detection. Mutation allelic frequency (MAF) was determined and validated through parallel analysis of matched H3.3K27M tissue specimens (n = 3). We determined technical nuances between ddPCR instruments, and optimized sample preparation and sequencing protocols for H3.3K27M mutation detection and quantification. We observed 100% sensitivity and specificity for mutation detection in matched DMG tissue and CSF across assays, platforms and institutions. ctDNA is reliably and reproducibly detected in the liquid biome using ddPCR, representing a clinically feasible, reproducible, and minimally invasive approach for DMG diagnosis, molecular subtyping and therapeutic monitoring.

Indexed as

Mutation RateBiomarkers, TumorBrain NeoplasmsChildCirculating Tumor DNAFeasibility StudiesGliomaHistonesHumansLiquid BiopsyPolymerase Chain ReactionPrognosisReference StandardsReproducibility of ResultsSensitivity and SpecificityBiomarkers, TumorCirculating Tumor DNAHistones

Identifiers

PMID33658570
PMCPMC7930089
OpenAlexW3135823466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.